⌘+K

Pulse Explore Communities Researchers Journals

Browser extensionInstagram

Home Communities Explore

May 14, 2023Open Access

[Expert consensus on the management of B-cell lymphoma-related cardiovascular diseases with Bruton tyrosine kinase inhibitors (2023)].

View Full Paper

Ask AI

Bookmark

Share

Structured PICO

P

Population

Patients with B-cell lymphoma receiving Bruton tyrosine kinase inhibitors

I

Intervention

Management of cardiovascular diseases

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Implication

Provides expert consensus on managing cardiovascular complications associated with Bruton tyrosine kinase inhibitors in B-cell lymphoma patients.

Abstract

Expert consensus on the management of B-cell lymphoma-related cardiovascular diseases with Bruton tyrosine

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

A 2023 study studied this question.

synapsesocial.com/papers/6a8a8a29b1e5d05ea8ecaaa6 https://doi.org/10.3760/cma.j.issn.0253-2727.2023.05.002

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context:

1Addressing cardiovascular toxicities of Bruton tyrosine kinase inhibitors in chronic lymphocytic leukaemia: practical recommendations for haematologists in central and eastern Europeguideline · 2025
2Cardiovascular Toxicity of BTK Inhibitors: A Patient-Centered Framework for Risk Stratification and Managementreview · 2026
3Australia and New Zealand consensus statement on the cardiovascular management of patients with chronic lymphocytic leukaemia treated with Bruton's tyrosine kinase inhibitorsguideline · 2025 · 4 citations
4Evidence-based expert consensus on clinical management of safety of Bruton’s tyrosine kinase inhibitors (2024)Original Research · 2024 · 15 citations
5Cardiovascular Challenges in Chronic Lymphocytic Leukemia ( <scp>CLL</scp> ) Patients Undergoing Bruton Tyrosine Kinase ( <scp>BTK</scp> ) Inhibitor Therapysystematic_review · 2025 · 11 citations
6Practical Management of Cardiovascular Adverse Events with BTKi Treatment in Patients with Chronic Lymphocytic Leukemia: A Consensus Report by Hematologists and Cardiologists2025 · 4 citations
7BTKi-induced cardiovascular toxicity in CLL: Risk mitigation and management strategiesreview · 2025 · 17 citations
84CPS-027 Analysis of cardiovascular risk associated with irreversible inhibitor of Bruton’s tyrosine kinase treatment in patients with chronic lymphoid leukaemia2024